98%
921
2 minutes
20
The complexity of implementing monitoring technology in healthcare presents numerous challenges, making it impractical for a small group of researchers to select observation windows and gather meaningful data. We developed a structured collaborative process involving about 20 individuals from informatics, data science, social science, practical implementation and healthcare to design protocols for investigating the implementation of monitoring technology in general ward and operating room settings through interviews, surveys and observations. Including practical implementation experts without research experience played a pivotal role, as their insights ground the protocols in practical realities. A Power-Interest Matrix is developed through an iterative process that incorporates the perspectives of those directly involved in the implementation. This matrix helps to identify and analyze key stakeholders, mapping their influence and interest in the implementation process and serves as a guide for engaging with relevant actors throughout the project.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3233/SHTI250359 | DOI Listing |
ACS Sens
September 2025
METU MEMS Center, Ankara 06530, Türkiye.
Cardiovascular diseases (CVDs) remain a leading cause of death, particularly in developing countries, where their incidence continues to rise. Traditional CVD diagnostic methods are often time-consuming and inconvenient, necessitating more efficient alternatives. Rapid and accurate measurement of cardiac biomarkers released into body fluids is critical for early detection, timely intervention, and improved patient outcomes.
View Article and Find Full Text PDFJAMA Cardiol
September 2025
Department of Medicine, Cardiovascular Medicine, Stanford University, Stanford, California.
Importance: Consumer wearable technologies have wide applications, including some that have US Food and Drug Administration clearance for health-related notifications. While wearable technologies may have premarket testing, validation, and safety evaluation as part of a regulatory authorization process, information on their postmarket use remains limited. The Stanford Center for Digital Health organized 2 pan-stakeholder think tank meetings to develop an organizing concept for empirical research on the postmarket evaluation of consumer-facing wearables.
View Article and Find Full Text PDFStem Cell Rev Rep
September 2025
Biomedical Centre Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Malá Hora 4C, Martin, 036 01, Slovakia.
Background: Several studies have suggested that adult human dermal fibroblasts (HDFa) may be a potential alternative source to mesenchymal stem cells for cell therapies. This study aims to characterize HDFa, adipose-derived stem cells (ADMSCs) and dental pulp stem cells (DPSCs) to investigate their proliferation, differentiation potential, mitochondrial respiration, and metabolomic profile. We identified molecules and characteristics that would differentiate MSCs from different sources or confirm their uniformity.
View Article and Find Full Text PDFMol Biol Rep
September 2025
School of Arts and Sciences, Department of Natural and Applied Sciences, The American University of Iraq-Baghdad, Baghdad, Iraq.
The COVID-19 pandemic, caused by the continuously evolving SARS-CoV-2 virus, has presented persistent global health challenges. As novel variants emerge, many with enhanced transmissibility and immune evasion capabilities, concerns have intensified regarding the efficacy of existing vaccines and therapeutics. This review provides a comprehensive overview of the current landscape of COVID-19 vaccination, including the development and performance of monovalent and bivalent boosters, and examines their effectiveness against newly emerging variants of interest (VOIs) and variants under monitoring (VUMs), such as JN.
View Article and Find Full Text PDFCurr Med Sci
September 2025
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Objective: To develop a novel prognostic scoring system for severe cytokine release syndrome (CRS) in patients with B-cell acute lymphoblastic leukemia (B-ALL) treated with anti-CD19 chimeric antigen receptor (CAR)-T-cell therapy, aiming to optimize risk mitigation strategies and improve clinical management.
Methods: This single-center retrospective cohort study included 125 B-ALL patients who received anti-CD19 CAR-T-cell therapy from January 2017 to October 2023. These cases were selected from a cohort of over 500 treated patients on the basis of the availability of comprehensive baseline data, documented CRS grading, and at least 3 months of follow-up.